SIGRID Therapeutics launches Carb Fence™, a new gut-local medical food designed to reduce the negative impact of modern meals. Powered by patented SiPore® technology, Carb Fence™ helps support steadier energy, fewer cravings, and lower post-meal glucose spikes by slowing digestion locally in the gut, offering a practical new approach to metabolic health in everyday life.
SIGRID Therapeutics announces the U.S. launch of Carb Fence™, its flagship medical food powered by patented SiPore® technology. The launch brings the clinically evaluated 9 g daily SiPore® dose to market for the first time, marking a major commercialization milestone following more than 15 years of research and multiple clinical studies.
Stockholm — January 21, 2026 — Sigrid Therapeutics (Sigrid) is a Swedish-based, science-driven consumer health company with a primary focus on metabolic health. Following the successful launch of its first two clinically proven products — Carb Fence , developed to support weight loss by reducing appetite and sugar cravings while promoting fat loss and preserving muscle mass , and Glucose Stabi
After an exceptionally successful online launch earlier this year, Sigrid Therapeutics and Kronans Apotek are now ready to take the next step: SIGRID Stabiliser will be launched on store shelves across the country in the fall of 2025.
SIGRID, the Swedish innovative consumer health company behind the patented SiPore® technology, today reports new clinical and commercial milestones for its innovative dietary supplement Glucose Stabiliser.
Sigrid Therapeutics today announced the signing of a strategic partnership with GetHealthy.store, a leading US provider of e-commerce solutions for healthcare providers selling healthcare and nutritional products.
Sigrid Therapeutics today announced that the company has launched Glucose Stabiliser in the US.
Sigrid Therapeutics has secured SEK 44 million in a successful and oversubscribed financing round, underscoring the strong confidence of investors in Sigrid's innovative SiPore technology®.
Sigrid Therapeutics (Sigrid), a Swedish consumer healthcare company, announced today that Professor Iain Chapple, a world-leading expert in oral health from the University of Birmingham's College of Medical and Dental Sciences, has been appointed as the company's scientific advisor.
Sigrid Therapeutics, an innovative, consumer-focused health company, today presented the results of a consumer trial ahead of the launch of their clinically proven SiPore® technology for blood sugar control in prediabetics and type 2 diabetics.
Sigrid Therapeutics, a Swedish consumer-focused technology company in consumer health, announced today that an additional SEK 10.6 million has been added to the company to accelerate the commercialization of its portfolio of dietary supplements based on SiPore®.
Sigrid Therapeutics, a Swedish consumer healthcare technology company, today announced that it has appointed Mattias Ankerberg as Chairman of the Board.
Sigrid Therapeutics, an innovative, consumer-focused health company that has developed a new technology, SiPore ® against prediabetes and obesity, announces today that the company, after 10 years of research, is in the starting blocks to launch its new, clinically proven product SiPore21 ® .
Swedish healthtech startup Sigrid Therapeutics is on its way to preventing two of the world's biggest health challenges, type 2 diabetes and obesity, with its SiPore15® powder.
Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO).
Sigrid Therapeutics AB, an innovative technology company developing a new class of products to improve human health, including type 2 diabetes, today announces that it has closed a rights issue of SEK 15.5 million.
Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies in metabolic diseases, today announces that all patients have completed treatment with SiPore15 in the STAR clinical trial.